Last reviewed · How we verify
PPV23 alone
PPV23 is a pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.
PPV23 is a pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease (bacteremia, meningitis, pneumonia) in adults and children ≥2 years, Prevention of pneumococcal pneumonia in high-risk populations (elderly, immunocompromised, chronic disease).
At a glance
| Generic name | PPV23 alone |
|---|---|
| Sponsor | Korea University Guro Hospital |
| Drug class | Polysaccharide vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (23 serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
PPV23 (Pneumovax 23) contains purified capsular polysaccharides from 23 different serotypes of pneumococcus conjugated to a carrier protein or presented as a polysaccharide mixture. Upon vaccination, these antigens trigger B-cell and T-cell responses, generating opsonizing antibodies that enhance phagocytosis and complement-mediated killing of pneumococcal bacteria, thereby providing protection against invasive pneumococcal disease and pneumonia caused by these serotypes.
Approved indications
- Prevention of invasive pneumococcal disease (bacteremia, meningitis, pneumonia) in adults and children ≥2 years
- Prevention of pneumococcal pneumonia in high-risk populations (elderly, immunocompromised, chronic disease)
Common side effects
- Injection site erythema, induration, or pain
- Fever
- Myalgia or arthralgia
- Headache
- Fatigue
Key clinical trials
- Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy (PHASE2)
- Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma (PHASE4)
- Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels (PHASE4)
- A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine (PHASE4)
- Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4 (PHASE4)
- Vaccinating Children After Chemotherapy (PHASE4)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) (PHASE3)
- Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |